These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8605092)

  • 21. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin-peptide conjugates overcome multidrug resistance.
    Mazel M; Clair P; Rousselle C; Vidal P; Scherrmann JM; Mathieu D; Temsamani J
    Anticancer Drugs; 2001 Feb; 12(2):107-16. PubMed ID: 11261883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
    Mayer LD; Lim KT; Hartley D
    J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
    Mankhetkorn S; Garnier-Suillerot A
    Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
    Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
    Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells.
    Zhou C; Shen P; Cheng Y
    Biochim Biophys Acta; 2007 Jul; 1770(7):1011-20. PubMed ID: 17451883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of multidrug-resistance cell line C(6)/adr and reversal of drug-resistance.
    Liu F; Wang C; Zhang Q; Li J; Zhang Y
    Chin Med J (Engl); 2002 Feb; 115(2):238-41. PubMed ID: 11940340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.
    Breuninger LM; Paul S; Gaughan K; Miki T; Chan A; Aaronson SA; Kruh GD
    Cancer Res; 1995 Nov; 55(22):5342-7. PubMed ID: 7585598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel highly potent and low-toxic jatrophane derivative enhancing the P-glycoprotein-mediated doxorubicin sensitivity of MCF-7/ADR cells.
    Maimaitijiang A; Wang B; Yang H; Tang D; Liu Y; Aisa HA
    Eur J Med Chem; 2022 Dec; 244():114822. PubMed ID: 36242992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
    Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
    Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression.
    McGrath T; Latoud C; Arnold ST; Safa AR; Felsted RL; Center MS
    Biochem Pharmacol; 1989 Oct; 38(20):3611-9. PubMed ID: 2573357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carnosine Potentiates Doxorubicin-Induced Cytotoxicity in Resistant NCI/ADR-RES Cells by Inhibiting P-Glycoprotein-In Silico and In Vitro Evidence.
    Morsy MA; Kandeel M; Ibrahim ARN; Abdel-Gaber SA; Jacob S; Venugopala KN; Shinu P; El-Daly M
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids.
    Wartenberg M; Frey C; Diedershagen H; Ritgen J; Hescheler J; Sauer H
    Int J Cancer; 1998 Mar; 75(6):855-63. PubMed ID: 9506530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
    Lee FY; Sciandra J; Siemann DW
    Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
    Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
    Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
    Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
    Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
    Consoli U; Van NT; Neamati N; Mahadevia R; Beran M; Zhao S; Andreeff M
    Leukemia; 1997 Dec; 11(12):2066-74. PubMed ID: 9447822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia HL-60 cells.
    Sedlák J; Hunáková L; Suliková M; Chorváth B
    Leuk Res; 1997 May; 21(5):449-58. PubMed ID: 9225074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
    J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.